SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Silexion Therapeutics Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.15+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $105.17K
- P/E (TTM)
- 0.0
- Dividend yield
- –
Silexion Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Silexion Therapeutics | Industry median |
|---|---|---|
| Market Cap | $180.52K | $166.30M |
| Enterprise Value | -$2.05M | $88.19M |
| PB Ratio | 4.10 | 2.03 |
| P/TBV Ratio | 4.10 | 2.29 |
Income (trailing twelve months)
| Measure | Silexion Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$14.13M | -$21.40M |
| Pretax Income | -$13.96M | -$14.34M |
| Net Income | -$13.96M | -$22.46M |
| EBITDA | -$14.13M | -$16.91M |
Returns
| Measure | Silexion Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -17022.0% | -53.2% |
| Return on Assets (ROA) | -278.0% | -40.9% |
| Return on Capital Employed (ROCE) | -5232.2% | -38.1% |
Balance sheet
| Measure | Silexion Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.23M | $61.43M |
| Net Cash (Debt) | $2.23M | $15.35M |
| Net Cash Per Share | $1.89 | $0.66 |
| Equity (Book Value) | $44.00K | $49.09M |
| Book Value Per Share | $0.04 | $1.37 |
| Tangible Book Value | $44.00K | $23.52M |
| Working Capital | -$235.00K | $76.81M |
Financial position
| Measure | Silexion Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.94 | 3.34 |
| Quick Ratio | 0.56 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Silexion Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$12.43M | -$12.35M |
| Capital Expenditures | -$2.00K | -$1.08M |
| Free Cash Flow | -$12.43M | -$20.22M |
| FCF Per Share | -$10.54 | -$0.42 |
Efficiency
| Measure | Silexion Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$997.00K | -$703.34K |
| Employee Count | 14 | 74 |
Dividends and yields
| Measure | Silexion Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -7732.3% | -23.3% |
| FCF Yield | -6886.9% | -8.72% |
Shares
| Measure | Silexion Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 1,179,840 | 58,127,000 |
| Shares Change (QoQ) | -62.3% | 0.54% |
Scores
| Measure | Silexion Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -31.28 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Silexion Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.